AVE logo

Avecho Biotechnology Limited Stock Price

ASX:AVE Community·AU$36.7m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

AVE Share Price Performance

AU$0.01
0.01 (233.33%)
AU$0.01
0.01 (233.33%)
Price AU$0.01

AVE Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with moderate risk.

5 Risks
1 Reward

Avecho Biotechnology Limited Key Details

AU$1.4m

Revenue

AU$520.9k

Cost of Revenue

AU$859.6k

Gross Profit

AU$4.5m

Other Expenses

-AU$3.6m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-0.00099
62.27%
-262.41%
0%
View Full Analysis

About AVE

Founded
1992
Employees
n/a
CEO
Paul Gavin
WebsiteView website
avecho.com.au

Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery. Its human health portfolio covers delivery of pharmaceutical products for pain and dermatology applications through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.

Recent AVE News & Updates

Recent updates

No updates